Posted by Michael Wonder on 14 Nov 2023
ICER publishes evidence report on treatment for pulmonary arterial hypertension
14 November 2023 - Sotatercept added to background therapy appears to improve clinical outcomes, but there are uncertainties on long term efficacy and safety; sotatercept would achieve common thresholds for cost effectiveness if priced between $18,700 -$36,200/year.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of sotatercept (Merck/MSD) for pulmonary arterial hypertension.
